Video

Our team behind the scenes at SXSW | Building a Disease Specific Knowledge Base

In part two of our SXSW series, our team shows how we use AI and machine learning to better understand specific diseases - in this case, Glioblastoma (GBM), the most common and aggressive form of brain cancer.

Given the complexity of a savage disease like GBM, a scientist alone could not read up on all the research that has been done to understand it. At BenevolentAI, we have developed a biomedical knowledge base to contextualise all the relevant information and relationships between diseases, genes, drugs and other important research that has already been published.

Our knowledge graph pulls out all the relevant links to ongoing and completed clinical trials, existing compounds that have been tested against the disease, and the underlying biological connections known to be associated with the disease. Together, these biological facts represent all that is known to be true about a disease today.

Our technology platform helps us understand diseases like GBM by sitting on top of this knowledge base and answering two fundamental questions, i) what do we know about the disease today? and ii) where are the gaps in that knowledge base?


Watch our team demonstrate how algorithms can analyse this knowledge and reason across it to provide scientists and researchers with capabilities beyond human insight.

More Posts

You Might Also Like

Video
Data & Digital Innovation for Climate & Health
Joanna Shields, CEO BenevolentAI, joined the Wellcome Trust Panel at the World Economic forum to discuss opportunities for data and digital innovation to impact positively climate and health.
Jan 26, 2023
News
BenevolentAI submits CTA for BEN-8744, an oral PDE10 inhibitor, as a first-in-class treatment for ulcerative colitis
BenevolentAI submits clinical trial application for BEN-8744, with a Phase I clinical trial planned for H1 2023.
Dec 21, 2022
News
BenevolentAI to present at 41st Annual J.P. Morgan Healthcare Conference
BenevolentAI ​​(Euronext Amsterdam: BAI), a leading clinical-stage AI drug discovery company, announces that it will participate in the upcoming 41st Annual J.P. Morgan Healthcare Conference in San Francisco, US from 9-12 January 2023.
Dec 1, 2022
Blog
FAIR Data Foundation: An Enabler for AI Drug Discovery
Biomedical data used in AI-enabled drug discovery should adhere to the FAIR Data Principles — Findability, Accessibility, Interoperability and Reusability. This blog explains why this is, how one can make data FAIR and challenges that remain.
Nov 8, 2022
News
BenevolentAI to present at Jefferies Investor Conference in November
BenevolentAI’s Investor Relations and Business Development team will be attending the Jefferies Healthcare London conference, with Nick Keher, CFO, presenting on Thursday 17th November.
Nov 4, 2022
News
BenevolentAI achieves further milestones in AI-enabled target identification collaboration with AstraZeneca
Two additional AI-generated novel targets selected by AstraZeneca for its drug development portfolio, resulting in two milestone payments for BenevolentAI.
Oct 6, 2022